NEW YORK (GenomeWeb) – Interleukin Genetics reported a 14 percent increase in total revenues year-over-year for the fourth quarter of fiscal year 2015.

For the three months ended Dec. 31, the Waltham, Massachusetts-based diagnostics firm said revenues increased to $365,648, up from $322,005 a year ago.

"We focused on developing and executing a significantly updated strategic and operational plan centered on the medical value of our genetic test, PerioPredict," Interleukin CEO Mark Carbeau said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.